Background
==========

Protein kinase D (PKD) constitutes a novel family of diacylglycerol (DAG)-responsive serine/threonine protein kinases with different structural, enzymological and regulatory properties from the protein kinase C (PKC) family members \[[@B1]-[@B3]\]. To date, three members of the PKD family have been identified: human PKD1 (its mouse ortholog being PKCμ), and the more recently identified PKD2 and PKD3 (also named PKCν), among which PKD1 is the most extensively characterized isoform. Emerging studies have revealed that PKDs are implicated in a complex array of fundamental biological activities, including cell survival \[[@B4]\], migration \[[@B5]\], proliferation \[[@B6]\], and immune responses \[[@B7]\]. In addition, growing evidence links PKDs to signal transduction pathways in tumor development and cancer progression. In many cases, specific PKD isoforms are dysregulated in cancer cells \[[@B8]\].

All PKDs share a common modular structure, with a tandem repeat of zinc finger-like cysteine-rich motifs at their NH~2~ termini that display high affinity for DAG or phorbol ester, a pleckstrin homology domain (PH domain) for negative regulation of kinase activity \[[@B9]\], and a C-terminal catalytic domain containing transphosphorylation and autophosphorylation sites. Activation of PKD isoforms is generally attributed to phosphorylation at a pair of highly conserved serine residues (for human: Ser^738^ and Ser^742^ in PKD1; Ser^706^ and Ser^710^ in PKD2; Ser^731^ and Ser^735^ in PKD3) in the activation loop of the kinase domain by PKC. As PKC can be activated by many extracellular signals, stimulation of PKD isoforms has been demonstrated by antigen receptor engagement \[[@B10]\], stimulation of receptor tyrosine kinases (RTKs) such as platelet-derived growth factors (PDGF) receptors \[[@B11]\] and vascular endothelial growth factor (VEGF) receptors \[[@B12]\], as well as activation of various G protein-coupled receptors (GPCRs). Among the large GPCR family, receptors with preferential coupling to G~q~, including those responsive to bombesin, vasopressin, endothelin, bradykinin \[[@B13]\], cholecystokinin \[[@B14]\], tachykinin \[[@B15]\] and angiotensin II have been demonstrated to activate PKD in a variety of cell types. Other G protein members like G~12~ and G~13~ have also been proposed to activate PKD3 in a PKC- and Rac-dependent manner \[[@B16]\]. In addition, it has been reported that G~q~, G~i~ and G~12/13~ may cooperate in LPA-induced PKD activation \[[@B17]\], but the relative contribution of specific G protein subunits (e.g. Gα~i~ versus Gβγ) to PKD activation remains undefined.

The functional specificity of G proteins was originally accredited to the Gα subunits, with the Gβγ dimers being viewed as negative regulators of G protein signaling. Yet, there is growing evidence that Gβγ dimers can also act as active mediators in signal transduction, thus conferring an additional level of signal specificity \[[@B18]-[@B20]\]. The Gβ identity in the Gβγ dimer imparts selectivity on its interaction with effectors like phospholipase Cβ \[[@B21]\], as well as in the regulation of neutrophil function \[[@B22]\]. Moreover, since the Gγ component is structurally and expression-wise diverse, it imposes additional complexity in signal transduction. For instance, only certain Gβγ combinations (mainly those containing γ~2~, γ~4~, γ~7~ or γ~9~) are linked to significant STAT3 activation \[[@B23]\]. Functional selectivity of Gγ subunits has also been reported \[[@B24]-[@B26]\]; deletion of the *Gng3* gene leads to increased susceptibility to seizures in mice with significant reductions in Gβ~2~ and Gα~i3~ subunit levels in certain brain regions \[[@B25]\], whereas knock-out of the *Gng7* gene is associated with reductions in the Gα~olf~ subunit content and adenylyl cyclase activity of the murine striatum \[[@B24]\]. These observations demonstrate that members of the Gγ subunit family are not functionally interchangeable.

It has been suggested that the interaction between Gβγ and the PH domain of PKD \[[@B27]\], or the Gβγ-induced PLCβ/PKC activity is critical for the induction of PKD activation \[[@B28]\].However, the relative contribution of these two apparently independent events to Gβγ-mediated PKD activation has yet to be addressed. Recently, Gβγ combinations containing Gγ~2~ (i.e. Gβ~1~γ~2~ and Gβ~3~γ~2~) have been shown to be effective activators for PKD \[[@B29]\], but the relevant capabilities of other Gβγ dimers remain unclear.

In this report, we demonstrated that all family members of the G~q~ subfamily (G~q~, G~11~, G~14~, and G~16~) can induce PKD1, PKD2 and PKD3 activation. G~s~ cannot elicit a PKD response, whereas G~i~ members may induce PKD activation in a Gβγ-dependent manner. For the Gβγ-induced PKD activation, even in the presence of PLCβ~2~ or PLCβ~3~, only certain Gβγ dimer combinations are capable of activating the kinase effectively. Moreover, we showed that this selective Gβγ dimer-mediated PKD activation is accompanied by enhanced interaction between the two components when PLCβ~2/3~ is present.

Materials and methods
=====================

Materials
---------

HEK293 and Jurkat T-cells were obtained from American Type Culture Collection (Rockville, MD). Pertussis toxin (PTX) was purchased from List Biological Laboratories (Campbell, CA). Cell culture reagents including Dulbecco's phosphate-buffered saline (PBS), trypsin, fetal bovine serum (FBS), penicillin-streptomycin mixture, RPMI 1640 medium, minimum essential medium (MEM), Dulbecco's modified Eagle's medium (DMEM) and Lipofectamine PLUS™ were obtained from Invitrogen (Carlsbad, CA). The cDNAs encoding PLCβ~1~, PLCβ~2~ and PLCβ~3~ were obtained from Dr. Richard Ye (University of Illinois at Chicago). Flag-tagged human Gβ~1~ and Gβ~2~, HA-tagged human Gγ~1~, Gγ~2~, Gγ~3~, Gγ~4~, Gγ~5~, Gγ~7~, Gγ~8~, Gγ~9~, Gγ~10~, Gγ~11~, Gγ~12~ and Gγ~13~ cDNA constructs were obtained from UMR cDNA Resource Center (Rolla, MO). Antiserum including anti-Flag and anti-HA were purchased from Roche Molecular Biochemicals (Indianapolis, IN). Cell culture reagents including Lipofectamine Plus™ were obtained from Invitrogen (Carlsbad, CA). Myo-\[^3^H\] inositol was purchased from DuPont NEN (Boston, MA). M2 affinity gels and protein A-agarose were obtained from Sigma (St. Louis, MO). HA-PKD1 and FLAG-PKD2 constructs were gifts from Dr. J. Van Lint (Katholieke Universiteit Leuven, Belgium), and Myc-PKD3 constructs were kindly provided by Dr. Q. J. Wang (University of Pittsburgh, PA).

Cell culture and transfection
-----------------------------

HEK293 cells were cultured in MEM supplemented with 10% (v/v) FBS, 50 units/ml penicillin, and 50 μg/ml streptomycin. Jurkat T-cells were cultured in RPMI1640 containing 10% (v/v) FBS. For PLC assays and co-immunoprecipitation assays, HEK293 cells were seeded at 60% confluency into 12-well plates or 6-well plates, respectively. Transfection was performed on the following day using Lipofectamine PLUS™ reagents. For the establishment of stable cell lines (293/BK~2~R, 293/β~2~AR and 293/fMLPR), exponentially growing HEK293 cells were transfected with cDNA of BK~2~R, β~2~AR or fMLPR in pcDNA3.1-zeo using Lipofectamine PLUS™. The cells were then selected with Zeocin (50 μg/mL). 293/fMLPR-Gα~16~ cells were established by transient transfection of 293/fMLPR stable cell lines with Gα~16~ in pcDNA3.

In vitro PKD Assay
------------------

Twenty-four hours after transfection, HEK293 cells were serum-starved overnight and then treated with 500 μl (per well) of ice-cold detergent-containing lysis buffer (50 mM Tris--HCl, pH 7.5, 100 mM NaCl, 5 mM EDTA, 40 mM Na~4~P~2~O~7~, 1% Triton X-100, 1 mM dithiothreitol, 200 μM Na~3~VO~4~, 100 μM phenylmethylsulfonyl fluoride, 2 μg/ml leupeptin, 4 μg/ml aprotinin, and 0.7 μg/ml pepstatin). Lysates obtained were subjected to *in vitro* PKD kinase assay. Fifty μl of each supernatant was used for the detection of PKD isoform expression and stimulatory phosphorylation, and the remaining lysate (450 μl) was incubated overnight at 4°C with specific affinity gels to immune-precipitate the corresponding PKD isoform (anti-HA for HA-PKD1; anti-FLAG for FLAG-PKD2; and anti-Myc for Myc-PKD3). The resulting immunoprecipitates were washed twice with lysis buffer and twice with kinase assay buffer (30 mM Tris--HCl, pH 7.4, 10 mM MgCl, and 1 mM DTT). Washed immunoprecipitates were resuspended in 40 μl of kinase assay buffer containing 2.5 mg/ml of Syntide-2 (PLARTLSVAGLPGKK), and the kinase reactions were initiated by the addition of 10 μl of ATP buffer containing 1 μCi of \[γ-^32^P\]-ATP per sample. After 10-min incubation at 30°C with occasional shaking, the reactions were terminated by adding 100 μl of 75 mM H~3~PO~4~ and spotting 75 μl of the reaction mix onto P-81 phosphocellulose paper. Free \[γ-^32^P\]-ATP was separated from the labelled substrate by washing the P-81 paper four times (5 min each) in 75 mM H~3~PO~4~. The papers were dried and the radioactivity incorporated into Syntide-2 was determined by scintillation counting.

Electroporation
---------------

The knock down of PKD1, PKD2 and PKD3 was performed by introducing the corresponding PKD isoform-specific siRNA from Invitrogen (Carlsbad, CA, USA) using Nucleofector® Kit V from Lonza (Basel, Switzerland). Briefly, 1×10^6^ cells per sample were resuspended in Nucleofector® Solution and supplement provided at room temperature. siRNA against PKD1, PKD2 or PKD3 (200 pmol each) was added to the samples and then electroporated using the Nucleofector®. Electroporated cells were then incubated at room temperature for 10 min before transferring them into the 12-well plate with culture medium. The knock down of PLCβ~1~, PLCβ~2~ and PLCβ~3~ was performed in similar manner, with the corresponding isoform-specific siRNA obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Western blotting analysis
-------------------------

Cells in 12-well plate were lysed in 300 μl of ice-cold lysis buffer (50 mM Tris--HCl, pH 7.5, 100 mM NaCl, 5 mM EDTA, 40 mM NaP~2~O~7~, 1% Triton X-100, 1 mM dithiothreitol, 200 μM Na~3~VO~4~, 100 μM phenylmethylsulfonyl fluoride, 2 μg/ml leupeptin, 4 μg/ml aprotinin and 0.7 μg/ml pepstatin). Clarified lysates were resolved on 1 μ2% SDS-polyacrylamide gels and then transferred to nitrocellulose membranes (Westborough, MA). Stimulatory phosphorylation of PKD1, PKD2, ERK and CREB were detected by their corresponding antisera and horseradish peroxidase-conjugated secondary antisera. The immunoblots were visualized by chemiluminescence with the ECL kit (Amersham Biosciences). Antibodies sources are as follows: anti-phospho-PKD1-Ser^744/748^, anti-phospho-PKD1-Ser^916^ (also recognize human PKD1-Ser^738/742^ and Ser^910^, respectively), anti-phospho-ERK-Thr^202^/Tyr^204^, anti-PKD1 were obtained from Cell Signaling Technology (Beverly, MA). Anti-phospho-PKD2-Ser^876^ and anti-PKD2 were purchased from R & D Systems (Minneapolis, MN). Anti-PKD3 was obtained from Bethyl Laboratories (Montgomery, TX).

Measurement of intracellular Ca^2+^ transient by FLIPR®
-------------------------------------------------------

Jurkat T-cells were serum-starved overnight in the absence or presence of PTX (10 ng/ml) and then washed with Hank's balanced salt solution (HBSS). Washed cells (1×10^6^ cells/ml) were preloaded with Fluo-4 (AM) followed by incubation at 37°C for 1 h. These labeled cells were then transferred to a black-walled and clear-bottomed 96-well plate (1×10^5^ cells/well) placed in the Fluorometric Imaging Plate Reader (FLIPR), and 50 μl of HBSS (with or without agonists) was added to each well. The resulting fluorescent signals that reflect the intracellular Ca^2+^ transients were monitored by an excitation wavelength of 488 nm and detection with the emission wavelength from 510 to 570 nm.

Co-immunoprecipitation assay
----------------------------

Transfected cells were lysed in the lysis buffer as described before. Cell lysates were centrifuged (12000 g, 4°C, 5 min) to remove cellular debris. Lysates were incubated at 4°C overnight with M2 affinity gels (20 μl/ sample) for the binding with Flag-tagged Gβ subunits. The resulting immunoprecipitates were collected by centrifugation at 1,000 g, 4°C, for 3 min and then washed three times with 500 μl lysis buffer. Bound proteins were eluted by 50 μl of lysis buffer and 10 μl of 6× SDS-containing sample buffer, and boiled μfor 5 min prior to separation by 12% SDS-polyacrylamide gel electrophoresis (PAGE). Flag-tagged Gβ, HA-tagged Gγ subunits, PLCβ~2~ and PKD1 in the immunoprecipitates were detected by their corresponding antisera followed with horseradish peroxidase-conjugated secondary antisera in Western blotting analysis.

Chemotactic assay
-----------------

The chemotactic ability of Jurkat T cells was evaluated using transwell plates (Costar, Cambridge, MA) with polycarbonate inserts with 5-μm pores (Costar 3421). Lower chambers were loaded with 600 μl of migration media alone or containing SDF-1α at the concentration of 100 nM. Cells (0.1 ml) at 1 × 10^6^/ml were added to the top chamber of a 24-well transwell (6.5-μm diameter, 5-μm pore size) and incubated for 4 h at 37°C. The cells which passed through the membranes and migrated to the lower chambers were quantified under microscopy.

Statistics
----------

The values shown in each figure represent mean ± SEM from at least three individual experiments. Statistical analyses were performed by ANOVA, followed by the Bonferroni's post test. Differences with a value of P \< 0.05 were considered statistically significant.

Results
=======

Previous studies on Gα subunit-induced activation of PKD isoforms were primarily performed on the PKD1 prototype with Gα~q~\[[@B30],[@B31]\], leaving the activation profile of the PKD family rather incomplete. Most of these studies employed aluminum tetrafluoride (AlF~4~^−^) to elicit G protein-mediated activation of PKD. Although AlF~4~^−^ can selectively stimulate heterotrimeric G proteins over monomeric GTPases \[[@B32],[@B33]\], AlF~4~^−^ activates multiple heterotrimeric G proteins simultaneously and thus cannot be used to identify the specific G proteins involved in the activation of PKD. On the basis of these considerations, we aimed to firstly define the role of different Gα subunits in promoting the activation of all three PKD isoforms. We performed screening on Gα subunit-mediated PKD1 phosphorylation. HEK293 cells were transfected with wild-type (WT) or constitutively active (RC/QL) Gα subunits (Gα~q~, Gα~11~, Gα~14~, Gα~16~, Gα~12~, Gα~13~, Gα~i1~, Gα~i2~, Gα~i3~, Gα~z~ and Gα~s~) and then assayed for PKD phosphorylation by phospho-PKD-specific antibodies. HEK293 cells have previously been shown to express all three PKD isoforms \[[@B34]\].

The phosphorylation of a pair of highly conserved serine residues in the activation loop (Ser^738^ and Ser^742^ in PKD1; Ser^706^ and Ser^710^ in PKD2; Ser^731^ and Ser^735^ in PKD3) plays a crucial role in human PKD activity \[[@B35]\]. Some early studies on PKD targeted the autophosphorylation sites (Ser^916^ in PKD1 and Ser^876^ in PKD2) as surrogate markers of mouse PKD activity, though a recent report has demonstrated that this site is not required for activation \[[@B36]\]. Therefore, anti-phospho-PKD1 Ser^744/748^ and Ser^916^ antibodies (also recognize human PKD1 at Ser^738/742^ and Ser^910^, respectively) were both adopted for the evaluation of PKD1 activation. As shown in Figure [1](#F1){ref-type="fig"}, expression of WT Gα subunits did not induce significant PKD1 phosphorylation as compared to the vector control, although expression of Gα~11~ or Gα~14~ slightly enhanced the basal PKD phosphorylation. Conversely, prominent phosphorylation of PKD1 was observed in cells expressing one of the constitutively active mutants from the Gα~q~ subfamily (Gα~q~, Gα~11~, Gα~14~, or Gα~16~). Western blot analysis verified that the expression levels of PKD1 were similar and that both WT and constitutively active Gα subunits were expressed at comparable levels (Figure [1](#F1){ref-type="fig"}). In contrast, there was no detectable phosphorylation of PKD1 by constitutively active mutants from G~i~, G~s~, or G~12~ subfamilies (Figure [1](#F1){ref-type="fig"}). This is consistent with earlier studies demonstrating that the constitutively active mutants of Gα~12~ and Gα~13~ did not induce PKD activation in COS-7 cells \[[@B30]\].

![**Constitutively active mutants of G**~**q**~**family members stimulate PKD1 phosphorylation.** HEK293 cells were transfected with pcDNA3, wild type (WT) or constitutively active (RC or QL) Gα subunits of G~q~, G~12~, G~i~ and G~s~ families. Transfectants were then lysed, and proteins were subjected to SDS-PAGE and immunoblotting with antibodies against phospho-PKD1, PKD1, and specific Gα subunits.](1478-811X-11-22-1){#F1}

To examine whether Gα subunits from the G~q~ subfamily are all capable of inducing activation of all three isoforms of PKD, HEK293/HA-PKD1, HEK293/FLAG-PKD2 and HEK293/Myc-PKD3 stable cell lines were established and then transiently transfected with WT or the RC/QL mutants of Gα subunits (Gα~q~, Gα~11~, Gα~14~, Gα~16~), followed by *in vitro* \[^32^P\]-kinase assays using syntide-2 as an exogenous substrate for PKD. As shown in Figure [2](#F2){ref-type="fig"}A, PKD isoforms isolated from all three stable cell lines transfected with vector control or plasmids encoding the WT Gα subunits exhibited low catalytic activity. In contrast, those immunoprecipitated from stable cell lines overexpressing a constitutively active mutant displayed marked increase in PKD kinase activity. Comparable expressions of Gα subunits and PKD isoforms in the various transfectants were confirmed by Western blot analyses (Figure [2](#F2){ref-type="fig"}B). We also examined the phosphorylation of specific PKD isoforms in the same samples. Since anti-phospho-PKD1^738/742^ exhibits some cross-reactivity with PKD2 and PKD3, anti-phospho-PKD1^910^ was also employed to detect PKD1 phosphorylation. Likewise, anti-phospho-PKD2^876^ was used for PKD2. As PKD3 lacks the phosphorylation site equivalent to phospho-PKD1^910^, only the phosphorylation at PKD3^731/735^ was monitored. In agreement with the results from the *in vitro* kinase assay, stimulatory PKD phosphorylation for all three PKD isoforms was enhanced in the presence of constitutively active Gα mutants from the G~q~ subfamily (Figure [2](#F2){ref-type="fig"}B). Unlike members of the G~q~ subfamily, constitutively active Gα~i1~ failed to stimulate the kinase activity of all three forms of PKD (Figure [2](#F2){ref-type="fig"}A) or elevate their level of phosphorylation (Figure [2](#F2){ref-type="fig"}B). Similar results were obtained with other members of the G~i~ (Gα~i2~, Gα~i3~, Gα~oA~, Gα~z~, Gα~t1~, and Gα~t2~), G~s~ (Gα~sL~ and Gα~olf~) and G~12~ (G~12~ and G~13~) families (Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1 and Additional file [2](#S2){ref-type="supplementary-material"}: Figure S2). Collectively, these results demonstrated that PKD1, PKD2 and PKD3 can be specifically activated by the constitutively active Gα subunits from the G~q~ family, but not by those of G~i~, G~s~ or G~12~ families.

![**All Gαsubunits from the G**~**q**~**subfamily can activate PKD1, PKD2 and PKD3.** (**A**) Stably expressed and epitope-tagged PKD isoforms were immunoprecipitated from HEK293 cells transiently co-transfected with Gα subunits, and syntide-2 phosphorylation assays were carried out as described under "Materials and Methods". Results are the average of at least three independent experiments, and presented as fold of control (±S.E.M.). (**B**) Cell lysates from HEK293 transfectants as described in (**A**) were subject to Western blot analysis using antibodies against specific Gα subunits (except anti-Gα~q~ which cross reacts with Gα~11~), phosphorylated PKD isoforms, PKD1, 2, 3 as well as their corresponding tag. Similar results were obtained in three separate experiments.](1478-811X-11-22-2){#F2}

The preceding experiments suggest that the Gα subunits from the G~q~ family contribute to elevated PKD phosphorylation. To examine in more detail the stimulation of PKD by G protein signaling, we tested different G~q~-, G~s~- and G~i~-coupled receptors for their ability to activate PKD1 in HEK 293 cells. HEK293 cells were transfected with the G~q~-coupled bradykinin BK~2~ receptor (Figure [3](#F3){ref-type="fig"}A), G~s~-coupled β~2~-adrenergic receptor (Figure [3](#F3){ref-type="fig"}B) or G~i~-coupled fMLP receptor (Figure [3](#F3){ref-type="fig"}C), and the transfectants subsequently examined for agonist-induced PKD1 activation. Phosphorylation of CREB or ERK was simultaneously monitored as positive controls of G~s~- and G~i~-signaling, respectively. In line with the data in Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}, only bradykinin (which stimulates the G~q~-coupled BK~2~ receptor) rapidly and potently stimulated PKD1 phosphorylation (Figure [3](#F3){ref-type="fig"}A), while isoproterenol and fMLP failed to induce any detectable PKD activation despite obvious phosphorylation of CREB or ERK (Figure [3](#F3){ref-type="fig"}B and C). Since many G~i~-coupled receptors including the fMLP receptor are capable of interacting with Gα~16~\[[@B37]\], it is expected that co-expression of Gα~16~ would turn on G~q~-related signals, thus allowing effective stimulation of PKD1 phosphorylation. As illustrated in Figure [3](#F3){ref-type="fig"}D, prominent fMLP-induced PKD1 phosphorylations at both Ser^738/742^ and Ser^910^ were observed in HEK293 cells co-expressing the G~i~-coupled fMLP receptor and Gα~16~ (Figure [3](#F3){ref-type="fig"}D); the fMLP-induced response was readily detected by 2 min and was maintained up to 30 min. These results further confirmed the specificity of Gα~q~-mediated PKD activation and implied that many GPCRs are capable of regulating the function of PKD through members of the G~q~ subfamily. This may have particular relevance to hematopoietic cells since the promiscuous Gα~16~ and Gα~14~ are mainly expressed in immune cells and are capable of recognizing a large number of GPCRs \[[@B38],[@B39]\].

![**G**~**q**~**, but not G**~**s**~**or G**~**i**~**signaling is linked to stimulatory phosphorylation of PKD in HEK293 cells.** HEK293 cells were stably transfected with BK~2~R (**A**), β~2~AR (**B**) or fMLPR, in the absence (**C**) or presence of Gα~16~ (**D**). Transfectants were serum starved for 4 h prior to treatment with 100 nM bradykinin (BK), 10 μM isoproterenol (ISO) or 300 nM N-formyl-methionyl-leucyl-phenylalanine (fMLP) for the indicated durations. Cell lysates were resolved in SDS-PAGE, and the presence of ERK, PKD and CREB phosphorylation was detected by their respective anti-phospho or anti-total antisera. Activation of PKD was observed only for BK~2~R and fMLPR/Gα~16~ stable cells. CREB activation served as a positive control for β~2~AR stable cells.](1478-811X-11-22-3){#F3}

Next, we investigated whether PKD phosphorylation can be induced upon activation of G~q~-coupled receptors that are endogenously expressed in HeLa cells. Serum starved HeLa cells were treated with various agonists targeting G~q~-, G~i~- and G~s~-coupled receptors for various durations, and PKD1 phosphorylation was determined by Western blot analysis. As expected, bradykinin and histamine acting on G~q~-coupled receptors effectively induced a marked increase in PKD phosphorylation at the activation loop (Figure [4](#F4){ref-type="fig"}A). Agonists that act on G~s~-coupled β-adrenergic receptor (isoproterenol) and GLP receptor (glucagon-like peptide) failed to activate PKD, even when stimulatory phosphorylation of ERK was clearly detected (Figure [4](#F4){ref-type="fig"}B). Unexpectedly, stimulation of G~i~-coupled α~2~-adrenergic receptor (by UK14304) and CXCR~4~ receptor (by SDF-1α) led to observable PKD activation. This is in contrast to the result presented in Figure [3](#F3){ref-type="fig"}C where stimulation of the G~i~-coupled fMLP receptor in HEK293 cells failed to promote PKD activation.

![**Stimulation of Gq/Gi-coupled receptors activates PKD1 in HeLa cells.** HeLa cells were serum starved, followed by treatment with (**A**) 100 nM bradykinin (BK) or 10 μM histamine (His); (**B**) 10 μM isoproterenol (ISO) or 100 nM glucagon-like peptide (GLP); (**C**) 10 μM UK14304 (UK14) or 100 nM stromal cell-derived factor-1 (SDF-1) for the indicated times. Cell lysates were detected for phospho-PKD, PKD, phospho-ERK and ERK with their respective anti-sera.](1478-811X-11-22-4){#F4}

The ability of G~i~-coupled receptors to stimulate PKD phosphorylation in HeLa cells was contrary to the results obtained with either Gα~i~QL (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}) or the G~i~-coupled fMLP receptor in HEK293 cells (Figure [3](#F3){ref-type="fig"}C). Given that Gα~q~-induced activation of PKD is known to be mediated via PLCβ/PKC \[[@B30]\], and that Gα~i~ apparently could not activate PKD, we hypothesized that PKD activation by the G~i~-coupled receptors in HeLa cells was mediated by the Gβγ subunits, presumably via Gβγ-sensitive PLCβ~2~ or PLCβ~3~. Gβγ-induced activation of PKD in HeLa cells have indeed been reported \[[@B27]\]. To test this hypothesis, we first examined the endogenous expression of PLCβ~2~ and PLCβ~3~ in both HEK293 and HeLa cells. Western blot analysis revealed that HEK293 cells expressed barely detectable levels of PLCβ~2~ and PLCβ~3~, whereas PLCβ~3~ (but not PLCβ~2~) was abundantly expressed in HeLa cells (Figure [5](#F5){ref-type="fig"}A).

![**PLCβ**~**2/3**~**is required for Gβγdimer-induced PKD activation.** (**A**), Expression of PLCβ~2~ and PLCβ~3~ in HEK293 and HeLa cells was determined with their respective anti-sera. HEK293 cells were transfected with pcDNA3 and Gβγ dimers with or without PLCβ~3~ (**B**) or PLCβ~2~ (**C**). PKD activation was detected by specific phospho-antibodies. Results shown are the mean ± S.E.M. of at least three independent experiments. (**D**) HEK293 cells were transfected with pcDNA3, PLCβ~2~, Gβγ with or without PLCβ~2~. Transfectants were lysed and the extracts analyzed by PLC assay or SDS-PAGE together with Western blot using antibodies against phosphorylated PKD1. Band intensity was quantified by Image J software (National Institute of Health, Bethesda, MD, USA) and depicted in graphical form, and presented as a fold-induction of the pcDNA3 control. Results shown are the mean ± S.E.M. of at least three independent experiments. (**E**) HeLa cells were transiently transfected with HA-tagged PKD1 together with vector control or Gβγ dimers. The expression of PKD1, FLAG-Gβ, HA-Gγ and endogenous PLCβ~3~ were detected with their specific antibodies.](1478-811X-11-22-5){#F5}

To determine the importance of Gβγ-sensitive PLCβ~2/3~ in Gβγ-mediated PKD activation, HEK293/Gγ~2~ stable cells were transiently transfected with FLAG-Gβ~1--2~, in the absence or presence of PLCβ~2/3~. Because consistent expression of Gγ subunits (\~6 kDa) is more difficult to achieve in transient transfections, HEK293 cells stably expressing Gγ~2~ were employed in these assays. As expected, co-expression of various combinations of Gβγ alone did not induce any stimulatory phosphorylation as compared to the vector control in HEK293 cells (Additional file [3](#S3){ref-type="supplementary-material"}: Figure S3A). Upon co-expression with PLCβ~3~, however, both Gβ~1~γ~2~ and Gβ~2~γ~2~ markedly enhanced the level of PKD phosphorylation; the expression of PLCβ~3~ alone had no significant effect on PKD phosphorylation (Figure [5](#F5){ref-type="fig"}B). Likewise, co-expression of Gβ~1~γ~2~ or Gβ~2~γ~2~ with PLCβ~2~ induced significant PKD phosphorylation (Figure [5](#F5){ref-type="fig"}C). These results not only suggest the crucial role of PLCβ~2/3~ in Gβγ-mediated PKD activation, but also help to explain the differences in G~i~-mediated PKD phosphorylation in HEK293 and HeLa cells.

Since the Gγ subunit identity has been shown to affect signaling specificity \[[@B24]-[@B26]\], we determined whether other Gβ~1~γ dimer combinations can effectively induce PKD1 activity in the presence of PLCβ~2/3~. Hence, HEK293 cells were transfected with pcDNA3 (vector control) and one of the twelve combinations of Gβ~1~γ~x~ dimer, with or without PLCβ~2~. As shown in Figure [5](#F5){ref-type="fig"}D (lower panel), transfection of Gβγ dimers alone did not significantly enhance the phosphorylation of PKD1 beyond the vector control. Among all of the Gβ~1~γ~x~ combinations tested, Gβ~1~γ~2~, Gβ~1~γ~3,~ Gβ~1~γ~4,~ Gβ~1~γ~5,~ Gβ~1~γ~7~ and Gβ~1~γ~10~ consistently triggered strong and significant PKD1 phosphorylation upon co-expression with PLCβ~2~, however, there was no significant change in PKD1 phosphorylation in other Gβ~1~γ~x~/PLCβ~2~-overexpressing cells (Figure [5](#F5){ref-type="fig"}D, lower panel). Comparable expressions of all Gβ~1~γ~x~ combinations and PLCβ~2~ were detected in the transfectants (data not shown), resulting in elevated levels of IP~3~ formation (Figure [5](#F5){ref-type="fig"}D, upper panel) as reported previously \[[@B21]\]. We also tested whether selected Gβ~1~γ~x~/PLCβ~2~ combinations can induce *in vitro* kinase activity of the different PKD isoforms (PKD1-3). In agreement with the Gβ~1~γ~x~/PLCβ~2~-induced PKD1 phosphorylation profile, Gβ~1~γ~2~/PLCβ~2~ and Gβ~1~γ~7~/PLCβ~2~ induced significant PKD kinase activity with all three PKD isoforms, while Gβ~1~γ~9~/PLCβ~2~ failed to do so (Additional file [3](#S3){ref-type="supplementary-material"}: Figure S3B). Similar Gβ~1~γ~x~-mediated PKD activation profile was obtained with PLCβ~3~ (data not shown). As expected, Gβ~1~γ~x~ failed to induce PKD phosphorylation with PLCβ~1~ which is insensitive to Gβγ (Additional file [3](#S3){ref-type="supplementary-material"}: Figure S3C).

Having demonstrated that certain Gβ~1~γ~x~/PLCβ~2/3~ combinations were more effective in triggering PKD activity in HEK293 cells, we asked if similar Gβ~1~γ~x~ selectivity for PKD phosphorylation could be observed in HeLa cells that endogenously express high level of Gβγ-sensitive PLCβ~3~ (Figure [5](#F5){ref-type="fig"}A). Due to the relatively low levels of endogenously expressed PKD1 \[[@B34]\], HeLa cells were transiently co-transfected with cDNAs encoding PKD1 and Gβ~1~γ~2~, Gβ~1~γ~7~ or Gβ~1~γ~9~, followed by serum starvation and subsequent immuno-detection of stimulatory phosphorylated PKD. The results obtained with endogenous PLCβ~3~-expressing HeLa cells (Figure [5](#F5){ref-type="fig"}E) were essentially similar to those obtained from the PLCβ~2/3~-transfected HEK293 cellular background (Figure [5](#F5){ref-type="fig"}D, lower panel). This further indicates that the identity of the Gγ subunit may confer specificity to Gβγ-mediated PKD phosphorylation.

It has previously been suggested that Gβγ activates PKD through direct interaction at its PH domain \[[@B27]\]. However, overexpression of Gβγ dimers failed to stimulate PKD phosphorylation in HEK293 cells (Figures [5](#F5){ref-type="fig"}B-D and Additional file [3](#S3){ref-type="supplementary-material"}: Figure S3A-B) unless Gβγ-responsive PLCβ~2/3~ was co-expressed (Figures [5](#F5){ref-type="fig"}D and Additional file [3](#S3){ref-type="supplementary-material"}: Figure S3B-C). Despite the fact that all of the functional Gβ~1~γ~x~ dimers tested are capable of stimulating PLCβ activity \[[@B21]\], only certain Gβ~1~γ~x~ dimers (e.g. Gβ~1~γ~2~) effectively stimulated PKD phosphorylation in the presence of PLCβ~2/3~ (Figure [5](#F5){ref-type="fig"}D, lower panel). Hence, we hypothesized that the presence of PLCβ~2/3~ may allow specific Gβγ to associate with PKD. For this, HEK293 cells were transiently transfected with pcDNA3 (vector control), Gβ~1~γ~x~ (Gβ~1~γ~7~, Gβ~1~γ~9~) with or without PLCβ~2~. FLAG-tagged Gβ~1~ was immunoprecipitated from the lysates of the transfectants, and the immune complexes were subjected to SDS-PAGE, followed by Western blotting for any PKD co-immunoprecipitated with Gβ~1~. As shown in Figure [6](#F6){ref-type="fig"}, phosphorylated PKD1 was clearly detectable in the immunoprecipitates prepared from transfectants expressing both Gβ~1~γ~7~ dimer and PLCβ~2~, but not when PLCβ~2~ was absent. Despite comparable expressions of the various constructs (Figure [6](#F6){ref-type="fig"}, right panel), hardly any PKD1 was pulled down by the FLAG-tagged Gβ~1~ in cells expressing Gβ~1~γ~9~ with or without PLCβ~2~ (Figure [6](#F6){ref-type="fig"}, left panel). It should be noted that both Gβ~1~γ~7~ and Gβ~1~γ~9~ were able to interact with PLCβ~2~ in a comparable manner because the latter was detected in the immunoprecipitates (Figure [6](#F6){ref-type="fig"}, left panel). As the current data showed that Gβγ dimers alone are ineffective in the co-immunoprecipitation with PKD, hence, our findings not only demonstrate the crucial role of PLCβ~2~ for the effective binding between Gβγ dimers and PKD, but also implicate that only specific Gβγ dimers are capable of interacting and activating PKD in the presence of PLCβ~2~.

![**Gβ**~**1**~**interacts with PKD1 in the presence of specific Gγsubunits and PLCβ**~**2**~**.** HEK293 cells were transiently transfected with pcDNA3, PLCβ~2~, and different Gβγ combinations as indicated, followed by serum starvation. Cell lysates were subjected to immunoprecipitation by FLAG-tagged affinity gel and SDS-PAGE to resolve for proteins bound to FLAG-Gβ~1~. Black lines represent positions at which images from the same blot but on different lanes were merged.](1478-811X-11-22-6){#F6}

Having established that PKD1-3 activation is promoted by ectopic expression of certain Gβγ complexes, we investigated whether Gβγ-mediated PKD activation was implicated in G~i~-linked biological function. Cell migration \[[@B34]\] and invasion \[[@B40]\] represent some of the known cellular functions of PKD. Since Jurkat T-cells express the G~i~-coupled receptor CXCR~4~ and it is responsive to stromal cell-derived factor 1α (SDF-1α) for chemotaxis \[[@B41]\], it appears to be a good cellular system for this investigation. First of all, we examined whether PLCβ~2~ and PLCβ~3~ are endogenously expressed in Jurkat T cells. Indeed, Jurkat T-cells endogenously express both PLCβ~2~ and PLCβ~3~ isoforms, with the former being more abundant (Figure [7](#F7){ref-type="fig"}A). Next, we used PTX (which ADP-ribosylates G~i~ proteins) to confirm that SDF-1α-induced signaling and chemotaxis in Jurkat T-cells are mediated via G~i~ proteins. Both SDF-1α-induced intracellular Ca^2+^ mobilization (Figure [7](#F7){ref-type="fig"}B) and chemotaxis (Figure [7](#F7){ref-type="fig"}C) in Jurkat T-cells were completely abolished upon PTX pretreatment. These results imply that CXCR~4~ utilizes G~i~ proteins to stimulate chemotaxis and PLCβ-mediated Ca^2+^ mobilization in Jurkat T cells. The latter response was presumably mediated by Gβγ dimers released from activated G~i~ proteins \[[@B42],[@B43]\].

![**SDF-1α-induced chemoataxis in Jurkat T cells is dependent on PTX-sensitive G**~**i**~**proteins and PKD2.** (**A**) Expression of PLCβ~2/3~ in Jurkat T cells were examined alongside with parental HEK293 cells or HEK293 cells overexpressing PLCβ~2/3~. (**B**) Bar diagram showing maximum SDF-1α-induced Ca^2+^ mobilization in Jurkat T cells with or without PTX pretreatment. (**C**) Jurkat T cells pretreated with or without PTX were subjected to SDF-1α-induced chemotactic assay. The chemotactic index was expressed as the ratio of the numbers of cells found in the lower compartments, between the agonist-stimulated and the unstimulated groups. (**D**) Jurkat T cells were pretreated with or without specific inhibitors for PKD (100 nM Gö6976), PI3K (100 nM wortmannin), and MEK/ERK (10 μM U0126) and then subjected to the chemotactic assay in the presence of SDF-1α. (**E**) Jurkat T cells pretreated with or without PTX were stimulated with 10 nM SDF-1α for the indicated durations. Cell lysates were subjected to immunoblotting for ERK and PKD2 phosphorylation. (**F**) Jurkat T cells were transfected with vehicle (RNase free water), scrambled siRNA (siCon), siPKD1, siPKD2 or siPKD3 oligonucleotides for 72 h prior to chemotactic assay. Cells were also harvested and lysates were subjected to Western blot analysis with specific antibody against PKD2. β-actin was used as loading control.](1478-811X-11-22-7){#F7}

To determine whether PKD contributed to SDF-1α-induced chemotaxis in Jurkat T cells, we asked if this chemotactic response can be inhibited by the PKD inhibitor, Gö6976. We were able to demonstrate that SDF-1α-induced chemotaxis could be suppressed by pretreatment with Gö6976 (Figure [7](#F7){ref-type="fig"}D). In agreement with a previous report \[[@B41]\], the PI3K inhibitor wortmannin (Figure [7](#F7){ref-type="fig"}D) also inhibited the SDF-1α-stimulated chemotaxis. Next, we assessed if PKD can be activated by the G~i~-coupled CXCR4. Jurkat T-cells were pretreated with or without PTX, followed by SDF-1α stimulation. Since Jurkat T-cells predominantly express PKD2 \[[@B44]\], only PKD2 phosphorylation was determined. SDF-1α stimulated PKD2 phosphorylation became evident within 10 min and peaked at 15 min after agonist addition (Figure [7](#F7){ref-type="fig"}E). The response was effectively abolished by PTX pretreatment of Jurkat T-cells. As a control, phospho-ERK was similarly monitored; SDF-1α also stimulated ERK phosphorylation in a PTX-sensitive manner (Figure [7](#F7){ref-type="fig"}E).

To substantiate that SDF-1α-induced chemotaxis in Jurkat T-cells is PKD2-dependent, we used specific validated siRNA oligonucleotides to knock down the expression of PKD2. As shown in Figure [7](#F7){ref-type="fig"}F, control and scrambled siRNAs had no effect on PKD2 expression, while silencing of PKD2 led to a remarkable reduction in PKD2 expression; siRNAs targeting either PKD1 or PKD3 did not affect the expression of PKD2. The siRNA-mediated knockdown of PKD2 effectively inhibited the SDF-1α-induced chemotaxis, whereas the controls and siRNAs targeting PKD1 and PKD3 did not significantly suppress chemotaxis (Figure [7](#F7){ref-type="fig"}F). Furthermore, silencing of PLCβ~2/3~ but not PLCβ~1~ resulted in the suppression of SDF-1α-induced chemotaxis in Jurkat T-cells, illustrating the importance of Gβγ-responsive PLCβ isoforms in this activity (Figure [8](#F8){ref-type="fig"}A). As SDF-1α also acts on G~i~-coupled CXCR4 receptor in HeLa cells for PKD activation (Figure [4](#F4){ref-type="fig"}C), we then performed similar knockdown treatment to verify the possible PLCβ~2/3~-dependency. Our result demonstrated that this G~i~-induced signaling also required the Gβγ-responsive PLCβ~2~/~3~ isoforms to stimulate the PKD activation (Figure [8](#F8){ref-type="fig"}B).

![**Requirement of Gβγ-responsive PLCβ**~**2/3**~**isoforms in SDF-1α-induced signaling activities in Jurkat T-cells and HeLa cells.** (**A**) Jurkat T-cells were transfected with the vehicle control (RNase free water), scrambled siRNA (siCon), siPLCβ~1~, or siPLCβ~2~ and siPLCβ~3~ oligonucleotides for 72 h prior to chemotactic assay upon SDF-1α treatment. Cells lysates were subjected to Western blot analysis with specific antibody against various PLCβ isoforms. β-actin was used as loading control. \*Simultaneous knockdown the Gβγ-responsive PLCβ~2~ and PLCβ~3~ isoforms resulted in significant suppression of SDF-1α-induced chemotaxis. (**B**) HeLa cells subjected to similar PLCβ knockdown profiles were examined for SDF-1α-induced PKD activation, the levels of phospho-PKD1 in cell lysates were detected by Western blot analysis. The fold-induction represents the ratio of band intensities (phospho-PKD1) with respect to the basal (1.00) of the control group. Similar results were obtained in two independent experiments.](1478-811X-11-22-8){#F8}

Discussion
==========

Extending from prior reports on the regulation of PKD1 by G~q~\[[@B30],[@B45]\], the present study demonstrates unequivocally that each and every member of the G~q~ subfamily (i.e., Gα~q~, Gα~11~, Gα~14~ and Gα~16~) are capable of inducing the kinase activity of all PKD isoforms (Figure [2](#F2){ref-type="fig"}). The ability to β stimulate PKD activity is apparently unique to the Gα~q~ members because other Gα subunits belonging to the G~i~, G~s~, or G~12~ subfamilies all failed to induce PKD phosphorylation or kinase activity (Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}, Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1 and Additional file [2](#S2){ref-type="supplementary-material"}: Figure S2). However, it should be noted that addition of AlF~4~^−^ to cells co-expressing PKD and wild type Gα~13~ can lead to PKD activation \[[@B46]\]. Such an observation is confounded by the fact that AlF~4~^−^ may activate multiple G proteins simultaneously. The lack of effect on PKD by the constitutively active mutant of Gα~13~ has in fact been reported \[[@B30]\]. Hence, it is reasonable to conclude that only members of the G~q~ subfamily are efficiently linked to PKD activation.

Despite the preponderance of G~q~ in mediating GPCR-induced activation of PKD, stimulation of G~i~-coupled receptors in HeLa cells resulted in PKD phosphorylation (Figure [4](#F4){ref-type="fig"}). This may be explained by the observation that HeLa cells endogenously express Gβγ-responsive PLCβ~2/3~\[[@B28]\], thereby allowing Gβγ released from activated heterotrimeric G~i~ proteins to mediate PKD activation through the Gβγ/PLC/PKC axis. One would expect that stimulation of G~i~-coupled receptors will result in PKD activation in cells endowed with PLCβ~2/3~. However, if the endogenous PLCβ~2/3~ is responsive to Gβγ dimers and all active G protein heterotrimers liberate free Gβγ dimers, then it remains puzzling why stimulation of G~s~-coupled receptors cannot activate PKD via PLCβ~2/3~ (Figure [4](#F4){ref-type="fig"}B). A recent report has revealed that differential dissociation may exist among different G proteins \[[@B47]\], though it has long been thought that active G protein heterotrimers readily dissociate into Gα*-*GTP subunits and Gβγ dimers \[[@B48]\]. Activated G~oA~ heterotrimers can seemingly dissociate more readily than activated G~s~ heterotrimers, and this may account for Gα-specific activation of Gβγ-sensitive effectors \[[@B47]\]. Alternatively, the lack of G~s~-induced PKD activation may be attributed to insufficient release of Gβγ dimers as most Gβγ-dependent signaling appeared to require substantial amounts of free Gβγ, which is most often achieved by stimulating the more abundantly expressed G~i~ proteins \[[@B42],[@B43]\].

Another interesting observation in the present study pertains to the requirement of PLCβ~2/3~ for Gβγ-induced PKD activation (Figure [5](#F5){ref-type="fig"}). At first sight, our finding seems to suggest a concept different from the previous belief that Gβγ dimers alone can activate PKD through interaction with the PH domain \[[@B27]\]. However, since the cellular model (i.e. HeLa cells) used in Jamora's report expresses significant amount of Gβγ-sensitive PLCβ~2/3~, it is possible that the presence of PLCβ~2/3~ enables specific Gβγ dimers to act on the PH domain of PKD. It has been demonstrated that Gγ prenylation is one of the important factors for Gβγ interaction with PLC isoforms, as the presence of farnesyl lipid motif in Gγ~1~, Gγ~9~ and Gγ~11~ may lead to a weaker PLC activation as compared to Gβγ dimers containing other Gγ components with geranylgeranyl lipid motif \[[@B49]\]. Indeed, we have observed that Gβ~1~γ~1~, Gβ~1~γ~9~ and Gβ~1~γ~11~ are associated with a weaker PLC activation and all of them are incapable of effectively stimulating PKD (Figure [5](#F5){ref-type="fig"}D and [5](#F5){ref-type="fig"}E). Hence, the possible influence of Gγ prenylation status cannot be neglected. However, Gβ~1~γ~2~ and Gβ~1~γ~3~ induce PLC activities of similar magnitude as those of Gβ~1~γ~12~ and Gβ~1~γ~13~, but only the former two are capable of stimulating PKD. As Gγ~2~, Gγ~3~, Gγ~12~, and Gγ~13~ are commonly incorporated with the geranylgeranyl lipid motif, factors other than Gγ prenylation and PLC activity may also be important for governing the specificity of Gβγ-mediated PKD activation. It can be observed that only certain Gβ~1~γ dimers (i.e., those containing γ~2~, γ~3~, γ~4~, γ~5~, γ~7~, and γ~10~) but not others (i.e., those containing γ~1~, γ~8~, γ~9~, γ~11~, γ~12~, and γ~13~) could effectively activate PKD in the presence of PLCβ~2/3~ (Figure [5](#F5){ref-type="fig"}D, lower panel). Yet, all combinations of Gβ~1~γ~x~ dimers are capable of activating PLCβ~2~\[[@B21]\]. The differential ability of various Gβ~1~γ dimers to stimulate PKD is thus unlikely to solely depend on their PLCβ activity alone. It can also be observed that the expression levels of Gβ~1~γ~4~, Gβ~1~γ~7~, Gβ~1~γ~9~, Gβ~1~γ~11~ and Gβ~1~γ~12~ appear to be increased upon PLCβ~2~ co-expression (Additional file [4](#S4){ref-type="supplementary-material"}: Figure S4). However, such increased Gβγ expression is not necessarily related to the subsequent PKD activation, as increased Gβ~1~γ~9~, Gβ~1~γ~11~ and Gβ~1~γ~12~ expressions do not effectively stimulate PKD in the presence of PLCβ~2~, whereas Gβ~1~γ~2~, Gβ~1~γ~3~, Gβ~1~γ~5~, and Gβ~1~γ~10~ trigger the kinase activation without increased levels of subunit expressions (Additional file [4](#S4){ref-type="supplementary-material"}: Figure S4). Hence, Gβγ-mediated PKD activation seems to be a specific function in response to unique Gβγ combinations.

In fact, the ability of specific Gβγ dimers to stimulate PKD phosphorylation may depend on their ability to form a complex with PKD, since only those Gβγ dimers that can stimulate PKD (e.g., Gβ~1~γ~7~) could be immunoprecipitated with PKD (Figure [6](#F6){ref-type="fig"}). The requirement of PLCβ~2/3~ in Gβγ-mediated PKD signaling might be explained if PLCβ~2/3~ is an essential component of the signaling complex that stabilizes the interaction between Gβγ and PKD. The possible existence of a Gβγ/PLCβ~2/3~/PKD signaling complex is supported by the fact that Gβγ dimers serve as direct activators for PLCβ~2/3~\[[@B50]\], probably through the binding of Gβγ to the PH domain of PLCβ~2/3~\[[@B51]\], while Gβγ/PKD-mediated Golgi fragmentation can be inhibited by a sequester peptide with identical sequence of the Gβγ-binding PH domain in PKD \[[@B27]\]. Indeed, we have preliminary data suggesting that PLCβ~2~ can be co-immunoprecipitated with all three PKD isoforms, while PLCβ~1~ fails to do so (Additional file [5](#S5){ref-type="supplementary-material"}: Figure S5). Apparently the reported capabilities of Gβγ to interact with PLCβ~2/3~ and PKD seem to support the notion for the formation of a Gβγ/PLCβ~2/3~/PKD signaling complex. However, it is unclear as to whether a single Gβγ dimer binds to the PH domains of PLCβ~2/3~ and PKD sequentially or simultaneously. Similarly, we cannot rule out the possibility that there may be different pools of Gβγ dimers for Gβγ-PLCβ and Gβγ-PKD interactions, respectively, and that they may subsequently cooperate with each other to stimulate PKD. Further studies are required to examine the precise interactions between Gβγ, PLCβ~2/3~ and PKD.

The assembly of a Gβγ/PLCβ~2/3~/PKD signaling complex may require the participation of scaffolding proteins. In this regard PKD isoforms have been shown to interact with the PDZ domains of a scaffolding protein family named NHERF \[[@B52]\]. Coincidently, PLCβ~2/3~ can also interact with different NHERF members \[[@B53],[@B54]\]. Hence, NHERF, as well as other similar scaffold proteins, may act as a nexus for Gβγ/PLCβ/PKD signaling (Figure [9](#F9){ref-type="fig"}), in which intracellular scaffold may facilitate or determine the formation of functional complexes among the signaling players. Scaffolding proteins (e.g. NHERFs and others) may form functional complexes with specific PLCβ isoforms and PKDs, and perhaps only those complexes containing PLCβ~2/3~ will enable Gβγ dimers to be recruited for interaction with PKDs. Such activation mechanism is not feasible for PLCβ~1~ which is Gβγ-insensitive. The Gβγ/PLCβ~2~/~3~-induced DAG production leads to confirmation changes of PKDs as well as PKC-mediated phosphorylation on the kinases. As demonstrated in the current report, enhanced Gβγ-induced PLCβ~2/3~ stimulation alone does not guarantee a successful PKD activation, it is possible that only specific Gβγ dimers (e.g. Gβ~1~γ~2~) are compatible with the PH domain of PKDs for productive conformation changes, which result in functional activation of PKDs. In fact, our unpublished data showed that PKD activation triggered by G~i~-coupled receptors is sensitive to inhibitors for PLCβ (e.g. U73122) as well as to Gβγ subunit scavengers (e.g. transducin). Since only specific Gβγ dimers are capable of stimulating PKD in the presence of PLCβ~2/3~, our results actually suggest a dual requirement of functional PLCβ activity and compatible Gβγ dimers for G~i~-mediated PKD activation. It remains unclear if all the members in the G~q~ family (i.e. Gα~q~, Gα~11~, Gα~14~, and Gα~16~) also activate PKD in a similar manner. However, it should be noted that another scaffold protein named PAR3 have been suggested as a G~q~-specific signaling component with selective recruitment of PLCβ~1~, while PLCβ~2/3~ isoforms may have high preferences towards NHERF members in G~i~-mediated signaling \[[@B53],[@B54]\]. The involvement of different scaffold proteins may also explain the differential observation that, Gα subunits of the G~q~ family (much stronger activators for PLCβ isoforms as compared to Gβγ dimers) are capable of stimulating PKD in a Gβγ-independent manner.

![**A schematic diagram for the Gβγ-mediated PKD activation.** PLCβ~2/3~ serves as important intermediates for the Gβγ-mediated PKD activation, in which intracellular scaffold proteins may facilitate or determine the formation of functional complexes among these signaling players. Scaffold proteins (e.g. NHERFs and others) may form functional complexes with specific PLCβ isoforms and PKDs, only those complexes containing PLCβ~2/3~ will enable Gβγ dimers to be recruited and interact with PKDs. The Gβγ/PLCβ~2~/~3~-induced DAG production leads to confirmation changes of PKDs as well as PKC-mediated phosphorylation on the kinases. As demonstrated in the current report, enhanced Gβγ-induced PLCβ~2/3~ stimulation alone does not guarantee a successful PKD activation, it is possible that only specific Gβγ dimers (e.g. Gβ~1~γ~2~) are compatible with the PH domain of PKDs for productive conformation changes, which result in functional activation of PKDs. Such activation mechanism is not feasible for PLCβ~1~ which is Gβγ-insensitive.](1478-811X-11-22-9){#F9}

PKD mediates a diverse array of normal biological functions and pathological activities, including cell proliferation and differentiation, cell motility, regulation of cell vesicle trafficking, secretion, and polarity, inflammatory responses, cardiac hypertrophy and cancer \[[@B55]\]. Therein, the transport of protein from the Golgi to plasma membrane is regulated via Gβγ signaling \[[@B27],[@B28],[@B56]\]. From our results, it is postulated that stimulation of G~i~-coupled receptor leads to the liberation of free Gβγ dimers, which then interact with PLCβ~2~/~3~ and activate PKD. This may help to elucidate part of the mechanism regarding secretory activities regulated by receptor-induced Gβγ translocation between the Golgi and plasma membrane \[[@B57]\], and the characteristic of Golgi as one of the major cellular locations for activated PKD \[[@B58]\]. Indeed, Gβγ dimers are known to mediate many cellular responses and signaling pathways involved in multiple aspects of cellular function. Previous studies have reported that SDF-1α-induced activation of CXCR4 receptor induces chemotaxis in Jurkat T cells \[[@B41]\]. Here, our results showed that this G~i~-coupled chemotactic response may be mediated by the Gβγ/PLCβ/PKD axis (Figure [7](#F7){ref-type="fig"}). However, further investigations are needed to determine whether these components act in concert. The activation of STAT3, which is an important transcription factor, is also regulated by Gβγ-mediated signaling \[[@B23]\]. Similar to PKD, only distinct combinations of Gβγ can effectively activate STAT3. Nevertheless, the panel of STAT3-activating Gβγ dimers is not identical to the PKD-stimulatory Gβγ complexes; only Gβ~1~γ~4~ and Gβ~1~γβ~7~ are effective activators for both pathways. Taken together, our results suggested that PKD may be implicated in diverse cellular activities, including those mediated by Gβγ.

Functional redundancy is a common feature among isoforms of biological molecules. However, it is not always the case. Though the three PKD isoforms are highly conserved and our results showed that all three PKD isoforms (PKD1, PKD2 and PKD3) are activated equally well by Gα subunits from the G~q~ family, as well as by specific Gβ~1~γ~x~ with PLCβ~2/3~, they may have unique functions. For example, PKD1 plays a non-redundant role in pathological cardiac remodeling, and the homozygous germline deletion of PKD1 causes embryonic lethality \[[@B59]\]. As for PKD2, it has a unique role in endothelial cells \[[@B6]\], lymphoid cells \[[@B7]\], and monocytes \[[@B34]\]. Recent studies have revealed the essential role of PKD3 in the progression of prostate cancer \[[@B60]\] and insulin-independent basal glucose uptake in L6 skeletal muscle cells \[[@B61]\]. Further studies are necessary to elucidate the mechanisms behind GPCR-mediated activation of the three PKD isoforms.

Conclusion
==========

Collectively, among various members of G proteins, only the Gα subunits of the G~q~ family effectively activate all three PKD isoforms (PKD1/2/3), while Gα subunits of other G protein families (G~s~, G~i~, and G~12~) are inefficient in these kinase activations. However, receptors linked to G~i~ proteins are capable of triggering PKD activation in cell lines endogenously expressing (HeLa cells and Jurkat T-cells) or exogenously transfected with (HEK293 cells) Gβγ-sensitive PLCβ~2/3~ isoforms, indicating the involvement of Gβγ dimers for the G~i~-mediated PKD activation. Although the presence of PLCβ~2/3~ is highly important, only those Gβ~1~γ dimers with γ~2~, γ~3~, γ~4~, γ~5~, γ~7~, and γ~10~ are effective activators of PKD, and the specific interaction between Gβγ, PKD and PLCβ~2/3~ may play a pivotal role in this Gβγ-mediated PKD signaling pathway. Furthermore, the biological significance of G~i~-mediated PKD activation is illustrated by SDF-1α-induced chemotaxis on Jurkat T-cells, in which the chemotaxic activity is abolished by pretreatment with PTX and knockdown of PKD. Taken together, our current report illustrates that Gβγ dimers from G~i~ proteins may activate PKD in a PLCβ~2/3~-dependent manner, and the identity of Gγ of the Gβγ dimer being a determinant.
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###### Additional file 1: Figure S1

Constitutively active Gα subunits from the G~i~ subfamily failed to induce PKD activation. (A) HEK293 cells were transiently transfected with pcDNA3 or WT/QL forms of Gα subunits from the G~i~ subfamily. Cell lysates were subjected to SDS-PAGE. Gα subunits, phospho-PKD1^738/742^, phospho-PKD1^910^, total PKD1, tag of PKD1 (HA) were analyzed by Western blotting using respective specific antibody. (B) HA-PKD1, FLAG-PKD2 and Myc-PKD3 were immunoprecipitated from cell lysates described in (A), and subjected to *in vitro* PKD kinase assays in terms of syntide-2 phosphorylation. Results are the average of at least three independent experiments, and represented as fold increase over pcDNA3 control (±S.E.M.).
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###### Additional file 2: Figure S2

Constitutively active Gα subunits from the G~s~ and G~12~ subfamilies failed to induce PKD activation. (A) HEK293 cells were transiently transfected with pcDNA3 or WT/QL forms of Gα subunits from the G~s~ and G~12~ subfamilies. Cell lysates were subjected to SDS-PAGE. Gα subunits, phospho-PKD1^738/742^, phospho-PKD1^910^, total PKD1, tag of PKD1 (HA) were analyzed by Western blotting using respective specific antibody. (B) HA-PKD1, FLAG-PKD2 and Myc-PKD3 were immunoprecipitated from cell lysates described in (A), and subjected to *in vitro* PKD kinase assays. Results are the average of at least three independent experiments, and represented as fold increase over pcDNA3 control (±S.E.M.).
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###### Additional file 3: Figure S3

PLCβ~2~ and specific Gγ subunits are required in Gβγ-induced PKD activation in HEK293 cells. (A) HEK293 cells stably transfected with pcDNA3 or HA-Gγ~2~ were transfected with pcDNA3, FLAG-Gβ~1~ or FLAG-Gβ~2~. Cell lysates were subjected to SDS-PAGE. FLAG-Gβ, HA-Gγ, phospho-PKD1^738/742^, phospho-PKD1^910^ and total PKD1 were analyzed by Western blotting using respective specific antibody. (B) HEK293 cells were transiently transfected with vector control, PLCβ~2~, various Gβγ dimers and tagged PKD isoforms (HA-PKD1, FLAG-PKD2 and Myc-PKD3). The cultures were then lysed, and the tagged PKD isoforms were immunoprecipitated for *in vitro* PKD kinase assay. (C) HEK293 cells transiently transfected with pcDNA3, Gβ, Gγ~x~, Gβγ combinations with or without PLCβ~1~ or PLCβ~2~ were lysed, and analyzed by Western blotting for PKD1 phosphorylation.

###### 

Click here for file

###### Additional file 4: Figure S4

The expression profiles of Gβγ dimers and the corresponding PKD activation in the presence of PLCβ~2~. HEK293 cells were transfected with pcDNA3, PLCβ~2~, various combinations of Gβγ with or without PLCβ~2~. Transfectants were lysed, and the lysates were subjected to Western blotting using antibodies against phosphorylated PKD1, PKD, PLCβ~2~, Flag-tagged Gβ~1~ and HA-tagged Gγ subunits.
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###### Additional file 5: Figure S5

PLCβ~2~, but not PLCβ~1~, can be co-immunoprecipitated with various PKD isoforms. HEK293 cells were transiently transfected with pcDNA3, PLCβ~1/2~ with tagged PKD1/2/3 as indicated. HA-PKD1, FLAG-PKD2 and Myc-PKD3 were immunoprecipitated from cell lysates with their respective affinity gels and further analyzed by Western blotting for the possible interaction with PLCβ~1/2~.
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